Central to AZAD`s strategy for its APIs is the establishment of proprietary intellectual property relating to synthetic routes and polymorphs, with use of cGMP approved CDMOs in territories that allow manufacture of patent-protected, highest quality – yet still cost-effective – products. Azad’s APIs are developed in Azad’s own Chemical Development labs in Armenia, and managed from the start until launch by our chemists in Schaffhausen.
AZAD’s strategy is to focus upon niche and complex generics, principally ophthalmics and parenterals, that present barriers / opportunities in terms of formulation and/or patents, and which require in-depth pharmaceutical knowledge to develop. AZAD`s experienced R&D scientists devise and if possible protect, unique formulations of FPs (Dossiers). Manufacturers of AZAD`s FPs are located primarily within the EU and Dossiers are in CTD-format, full regulatory / pharmaceutical support being provided by AZAD to facilitate a rapid registration process and thus speed to market.